(RTTNews) - Targeted Genetics Corp. (TGEN | charts | news | PowerRating) presented interim data this week from a Phase II trial of tgAAC09 in Africa. The company said that the tgAAC09 vaccine candidate utilizes an adeno-associated virus or AAV vector to deliver genes encoding HIV proteins and is designed to stimulate an immune response against HIV.
In this double-blind, randomized, placebo-controlled study, 91 healthy HIV-negative volunteers at five clinical sites in Africa have received two intra-muscular injections of placebo or tgAAC09 at 3 different dosage levels either six or 12 months apart.
The company noted that the reported safety data reflect results following the first vaccination and re-vaccination in 91 and 82 volunteers, respectively. To date, the vaccine has been well tolerated, and no severe local or systemic reactions to vaccination have been reported.
read more
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment